Brief: Matinas Biopharma- Non-Inferiority Trial Will Enroll About 216 Patients With Primary Endpoint Of All-Cause Mortality

Matinas BioPharma Holdings

20/02/2024 12:36

Feb 20 (Reuters) - Matinas BioPharma Holdings Inc
 MTNB.A :
    * MATINAS BIOPHARMA SUCCESSFULLY REACHES AGREEMENT WITH FDA
FOR A
SINGLE PHASE 3 REGISTRATION TRIAL TO SUPPORT AN NDA FOR MAT2203
FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS
    * MATINAS BIOPHARMA HOLDINGS INC - NON-INFERIORITY TRIAL
WILL
ENROLL APPROXIMATELY 216 PATIENTS WITH PRIMARY ENDPOINT OF
ALL-CAUSE MORTALITY AT DAY 42

Source text for Eikon:  ID:nGNX6nLbr8 
Further company coverage:  MTNB.A 

 ((Reuters.Briefs@thomsonreuters.com;))